Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Vemircopan in Healthy Participants
NCT05047484Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (6 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Number Of Participants Experiencing Serious Adverse Events, Number Of Participants Experiencing Grade 3 Or 4 Adverse Events and 3 more. Started Jan 2019; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05047484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047484.